These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 9636465)

  • 1. Risks and benefits of withdrawing cyclosporine from the long-term immunosuppression regimen of heart and heart-lung transplant recipients.
    Walker S; Habib S; Thompson D; Khaghani A; Yacoub M; Banner N
    Transplant Proc; 1998 Jun; 30(4):1149-51. PubMed ID: 9636465
    [No Abstract]   [Full Text] [Related]  

  • 2. Neoral versus Sandimmun: clinical impact and modification of immunosuppressive therapy in cardiac transplantation.
    Maccherini M; Bernazzali S; Diciolla F; Giunti G; Bizzarri F; Lisi GF; Davoli G; Biagioli B; Giomarelli PP; Simeone F; Caciorgna M; Marchetti L; Pula G; Sani G; Toscano M
    Transplant Proc; 1998 Aug; 30(5):1904-5. PubMed ID: 9723327
    [No Abstract]   [Full Text] [Related]  

  • 3. Azathioprine withdrawal in stable lung and heart/lung recipients receiving cyclosporine-based immunosuppression.
    Hoffmeyer F; Hoeper MM; Spiekerkötter E; Harringer W; Haverich A; Fabel H; Niedermeyer J
    Transplantation; 2000 Aug; 70(3):522-5. PubMed ID: 10949197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoral conversion study: shift from Sandimmune classic formulation to Neoral in heart and lung transplant patients.
    Svendsen UG; Larsen KR; Allermand H; Thayssen P; Jensen SB; Pettersson G
    Transplant Proc; 1996 Aug; 28(4):2281. PubMed ID: 8769225
    [No Abstract]   [Full Text] [Related]  

  • 5. Primary immunosuppression with tacrolimus and mycophenolate mofetil versus cyclosporine and azathioprine in heart transplant recipients.
    Teebken OE; Strüber M; Harringer W; Pichlmaier MA; Haverich A
    Transplant Proc; 2002 Jun; 34(4):1265-8. PubMed ID: 12072335
    [No Abstract]   [Full Text] [Related]  

  • 6. Relative clinical impact of cyclosporine vs steroid induction therapy on renal function and allograft rejection in heart transplant recipients.
    Hanrahan JS; Ibrahim H; Tolman D; Kirchberg D; Salter D; Guerraty A; Mohanty PK
    Transplant Proc; 1996 Aug; 28(4):2107-8. PubMed ID: 8769168
    [No Abstract]   [Full Text] [Related]  

  • 7. Conversion from regular cyclosporine to microemulsion cyclosporine following heart transplantation.
    Heroux AL; LeBlanc MH; Beaudoin D; Simard S; Coulombe DA; Gleeton O; Lemieux MD; Doyle DP
    Transplant Proc; 1996 Dec; 28(6):3145-8. PubMed ID: 8962219
    [No Abstract]   [Full Text] [Related]  

  • 8. Behavior of International Society for Heart and Lung Transplantation grade 2 cardiac rejection.
    Milano A; Livi U; Caforio AL; Bianco R; Casula R; Gambino A; Feltrin G; Legittimo A; Angelini A; Thiene G
    Transplant Proc; 1994 Oct; 26(5):2724. PubMed ID: 7940853
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term outcome with the use of OKT3 induction therapy in heart transplant patients: a single-center experience.
    Adamson R; Obispo E; Dychter S; Dembitsky W; Moreno-Cabral R; Jaski B; Gordon J; Hoagland P; Moore K; King J; Andrews J; Rich M; Daily PO
    Transplant Proc; 1998 Jun; 30(4):1107-9. PubMed ID: 9636449
    [No Abstract]   [Full Text] [Related]  

  • 10. Cyclosporine-based steroid-free therapy in pediatric heart transplantation: long-term results.
    Livi U; Caforio AL; Gambino A; Tursi V; Milanesi O; Stellin G; Angelini A; Casarotto D
    Transplant Proc; 1998 Aug; 30(5):1975-6. PubMed ID: 9723358
    [No Abstract]   [Full Text] [Related]  

  • 11. Improved survival after lung transplantation in patients treated with tacrolimus/mycophenolate mofetil as compared with cyclosporine/azathioprine.
    Izbicki G; Shitrit D; Aravot D; Sulkes J; Saute M; Sahar G; Kramer MR
    Transplant Proc; 2002 Dec; 34(8):3258-9. PubMed ID: 12493439
    [No Abstract]   [Full Text] [Related]  

  • 12. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder.
    Preiksaitis JK; Diaz-Mitoma F; Mirzayans F; Roberts S; Tyrrell DL
    J Infect Dis; 1992 Nov; 166(5):986-94. PubMed ID: 1328412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of cyclosporine: influence of covariables and assessment of cyclosporine absorption in kidney, lung, heart and heart + lung transplanted patients.
    Kyhl LE; Rasmussen SN; Aarons L; Jensen SB
    Transplant Proc; 1998 Aug; 30(5):1680. PubMed ID: 9723241
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical impact of Neoral in thoracic organ transplantation.
    Aziz T; el-Gamel A; Keevil B; Krysiak P; Campbell C; Rahman A; Deiraniya A; Yonan N
    Transplant Proc; 1998 Aug; 30(5):1900-3. PubMed ID: 9723326
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of cyclosporine monitoring with trough levels to levels obtained 6 hours after the morning dose in heart transplant patients: a prospective randomized study.
    Cantarovich M; Latter D; Fitchett D
    Transplant Proc; 1997; 29(1-2):602-4. PubMed ID: 9123149
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of Sandimmune, Neoral, and Prograf on rejection incidence and renal function in primary liver transplant recipients.
    Van Buren D; Payne J; Geevarghese S; MacDonell R; Chapman W; Wright JK; Helderman JH; Richie R; Pinson CW
    Transplant Proc; 1998 Aug; 30(5):1830-2. PubMed ID: 9723299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits of mycophenolate mofetil in cardiac transplant recipients with cyclosporine-induced nephropathy.
    Sánchez V; Delgado JF; Blasco T; Dalmau R; Morales JM; Escribano P; Tello R; Hernández J; Velázquez T; Sotelo T; Gómez-Sánchez MA; Sáenz de la Calzada C
    Transplant Proc; 1999 Sep; 31(6):2515-6. PubMed ID: 10500695
    [No Abstract]   [Full Text] [Related]  

  • 18. Does early steroid withdrawal influence rejection and infection episodes during the first 2 years after heart transplantation?
    Seydoux C; Berguer DG; Stumpe F; Hurni M; Ruchat P; Fischer A; Müller X; Sadeghi H; Goy JJ
    Transplant Proc; 1997; 29(1-2):620-4. PubMed ID: 9123157
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of cyclosporine A monotherapy on the incidence of rejection and infection episodes in heart transplant patients.
    Seydoux C; Stumpe F; Hurni M; Ruchat P; Fischer A; Mueller X; von Segesser L; Goy JJ
    Transplant Proc; 1998 Dec; 30(8):4037-43. PubMed ID: 9865288
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term results of triple-drug-based immunosuppression in nonneonatal pediatric heart transplant recipients.
    Gajarski RJ; Smith EO; Denfield SW; Rosenblatt HM; Kearney D; Frazier OH; Radovancevic B; Price JK; Kertesz NJ; Towbin JA
    Transplantation; 1998 Jun; 65(11):1470-6. PubMed ID: 9645805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.